Sai Life Sciences shareholders adopted the audited standalone and consolidated financial statements for FY26 at the company’s 27th Annual General Meeting (AGM). The meeting was held on September 17, 2026, via video conferencing.

The event transacted ordinary business items as outlined in the notice. Shareholders also approved the re-appointment of Mr. Krishnam Raju Kanumuri as a director, replacing himself upon retirement by rotation.

Meeting Proceedings

The AGM commenced at 10:30 am with Dr. Kanumuri Ranga Raju, Chairman and Whole Time Director, calling the meeting to order. Due to technical issues, Mr. Sivaramakrishnan Chittor, Whole-Time Director and Chief Financial Officer, addressed the shareholders on behalf of Mr. Krishnam Raju Kanumuri, Managing Director and Chief Executive Officer.

Mr. Chittor presented an overview of the company’s financial performance for FY26. He highlighted key operational achievements and outlined the growth strategy expected to drive value creation for stakeholders.

Key Attendees

The following directors were present at the meeting:

• Dr. Kanumuri Ranga Raju, Chairman & Whole Time Director
• Mr. Krishnam Raju Kanumuri, Managing Director & CEO
• Mr. Sivaramakrishnan Chittor, Whole-time Director & CFO
• Mr. Dinesh Vinoobhai Patel, Independent Director
• Mr. Ramesh Ganesh Iyer, Independent Director
• Ms. Suchita Sharma, Independent Director

Ms. Runa Karan, Company Secretary & Compliance Officer, welcomed members and confirmed compliance with Ministry of Corporate Affairs and SEBI circulars regarding virtual meetings.

Voting Results and Analysis

Remote e-voting facilities were provided through KFin Technologies Limited from September 14 to September 16, 2026. Mr. DSM Ram was appointed as the scrutinizer for the voting process. The record date for the meeting was September 10, 2026.

Members holding 7,76,98,047 equity shares participated in the meeting. The auditor’s report contained no qualifications, observations, or adverse comments on the financial statements. Similarly, the secretarial audit report had no adverse remarks.

The meeting concluded at 11:25 am after all resolutions were passed with the requisite majority. Below are the detailed voting outcomes for the two ordinary resolutions considered.

Resolution 1: Adoption of Financial Statements

The resolution to adopt the Audited Standalone and Consolidated Financial Statements for the year ended March 31, 2026, received overwhelming support. Promoter group shareholders voted 100% in favour. Among public shareholders, institutional investors also voted unanimously in favour, while non-institutional public shareholders recorded negligible dissent.

Resolution 2: Re-appointment of Director

The resolution to re-appoint Mr. Krishnam Raju Kanumuri as a director passed with a majority, though it faced notable dissent from public institutional investors. While promoter shareholders voted unanimously in favour, public institutions cast approximately 1.82% of their polled votes against the resolution. Non-institutional public shareholders largely supported the re-appointment.

Scrutinizer Report Details

The consolidated scrutinizer report, issued by DSM Ram of DSMR & Associates, confirmed that the e-voting process complied with Section 108 of the Companies Act, 2013 and relevant SEBI Listing Regulations. The report noted that invalid votes were primarily from public institutions, totaling 110,460 votes for Resolution 1 and 96,899 votes for Resolution 2.

Sai Life Sciences will host company officials at the Jefferies 5th India Forum in Gurugram on September 18, 2026. The event runs from 9:00 am to 6:00 pm IST.

The pharma firm disclosed the schedule under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. Discussions will be conducted in person through group and one-on-one sessions.

Company representatives will base all discussions on publicly available information. No unpublished price-sensitive information will be shared during the meetings.

The schedule remains subject to change due to exigencies involving participants or the company. Investors and analysts may approach Sai Life Sciences for clarifications regarding the discussions after the event.